This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kodityal, S. Articles by Rice, L. Search for Related Content PubMed PubMed Citation Articles by Kodityal, S. Articles by Rice, L. Social Bookmarking                         What's this?

Argatroban for Suspected Heparin-Induced Thrombocytopenia: Contemporary Experience at a Large Teaching Hospital

Baylor College of Medicine

Phuong H. Nguyen, PharmD

Baylor College of Medicine, The Methodist Hospital, Houston, TX

Amith Kodityal, BA

Baylor College of Medicine

Jeff Sherer, PharmD

The Methodist Hospital, Houston, TX

Marcie J. Hursting, PhD

Clinical Science Consulting, Potomac, MD

Lawrence Rice, MD

Baylor College of Medicine, The Methodist Hospital, Houston, TX, lrice{at}bcm.tmc.edu

Heparin-induced thrombocytopenia requires immediate alternative anticoagulation to prevent or treat thromboembolic complications. Argatroban was approved based on multiple-center studies from the 1990s, but subsequent changes in prevailing awareness, diagnostic testing and therapeutic strategies for heparin-induced thrombocytopenia might affect results of argatroban therapy. Charts were retrospectively reviewed from patients administered argatroban for suspected heparin-induced thrombocytopenia over 22 months at a single large university hospital. Twenty-seven patients, most in intensive care units, received a median 0.5 µg/kg/min argatroban over a median 5.5 days. Patients had isolated heparin-induced thrombocytopenia (n = 10), had heparin-induced thrombocytopenia with thrombosis (n = 9), or lacked active heparin-induced thrombocytopenia (n = 8) on final analysis. New thromboses (14.8%), progression of preexisting thromboses (0%), amputation secondary to heparin-induced thrombocytopenia (0%), death (22.2%), bleeding requiring transfusion (3.7%), and any bleeding (22.2%) compared favorably with older multiple-center reports. Deaths occurred mainly with preexisting multiple-organ failure. In contemporary "real world" use, argatroban provides safe and effective anticoagulation, strengthening the mandate to initiate alternative anticoagulation whenever heparin-induced thrombocytopenia appears likely.

Key Words: argatroban • heparin-induced thrombocytopenia • anticoagulants • direct thrombin inhibitors

Journal of Intensive Care Medicine, Vol. 21, No. 2, 86-92 (2006)
DOI: 10.1177/0885066605284590


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. P Keegan, E. M Gallagher, N. E Ernst, E. J Young, and E. W Mueller Effects of Critical Illness and Organ Failure on Therapeutic Argatroban Dosage Requirements in Patients with Suspected or Confirmed Heparin-Induced Thrombocytopenia Ann. Pharmacother., January 1, 2009; 43(1): 19 - 27. [Abstract] [Full Text] [PDF]

				S. M. Begelman, S. B. Baghdasarian, I. M. Singh, M. A. Militello, M. J. Hursting, and J. R. Bartholomew Argatroban Anticoagulation in Intensive Care Patients: Effects of Heart Failure and Multiple Organ System Failure J Intensive Care Med, September 1, 2008; 23(5): 313 - 320. [Abstract] [PDF]

				T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]

				M. A. Crowther and T. E. Warkentin Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents Blood, May 15, 2008; 111(10): 4871 - 4879. [Abstract] [Full Text] [PDF]

				W. D Hoffman, Y. Czyz, D. A McCollum, and M. J Hursting Reduced Argatroban Doses After Coronary Artery Bypass Graft Surgery Ann. Pharmacother., March 1, 2008; 42(3): 309 - 316. [Abstract] [Full Text] [PDF]

				L. Rice, M. J. Hursting, G. M. Baillie, and D. A. McCollum Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin-induced Thrombocytopenia J. Clin. Pharmacol., August 1, 2007; 47(8): 1028 - 1034. [Full Text] [PDF]

				T. E. Warkentin Think of HIT Hematology, January 1, 2006; 2006(1): 408 - 414. [Abstract] [Full Text] [PDF]